What is new in non-muscle-invasive bladder cancer in 2016?
- 21 February 2017
- journal article
- review article
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal Of Urology
- Vol. 43 (1), 9-13
- https://doi.org/10.5152/tud.2017.60376
Abstract
Approximately 75% of bladder cancers are non-muscle-invasive bladder cancer (NMIBC), and 50% of NMIBC patients who are treated with transurethral resection (TUR) have a recurrence of the disease and 5-25% of these patients progressed to muscle-invasive disease after repeated recurrences. NMIBC patients receive various treatments aimed at reducing disease recurrence and progression. Although the recurrence rate of disease remains above target, thus increasing treatment cost, the true rate of recurrence after the primary surgery is controversial. Recurrences can be categorized as either true recurrence due to aggressive tumor biology and implantation of floating cancer cells or false recurrence such as small, flat, or carcinoma in situ lesions overlooked in the primary procedure. Here we discuss new diagnostic methods and treatment options to improve outcomes and reduce recurrence rates in NMIBC.Keywords
This publication has 34 references indexed in Scilit:
- The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer – A New AnalysisBladder Cancer, 2016
- A Comparison of the Progression and Recurrence Risk Index in Non-Muscle-Invasive Bladder Tumors Detected by Narrow-Band Imaging Versus White Light Cystoscopy, Based on the EORTC Scoring SystemNephro-Urology Monthly, 2016
- Urinary Biomarkers for Diagnosis of Bladder CancerAnnals of Internal Medicine, 2015
- Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation.World Journal of Urology, 2015
- Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-GuérinBJU International, 2015
- Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancerNature Reviews Urology, 2015
- International Variations in Bladder Cancer Incidence and MortalityEuropean Urology, 2013
- Narrow band imaging diagnosis of bladder cancer: systematic review and meta‐analysisBJU International, 2012
- The Role of Tumor-Free Status in Repeat Resection Before Intravesical Bacillus Calmette-Guerin for High Grade Ta, T1 and CIS Bladder CancerJournal of Urology, 2010
- Urine Markers for Bladder Cancer Surveillance: A Systematic ReviewEuropean Urology, 2005